Effect of OPC Factor on Energy Levels

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00318019
First received: April 21, 2006
Last updated: November 16, 2011
Last verified: November 2011

April 21, 2006
November 16, 2011
June 2006
April 2008   (final data collection date for primary outcome measure)
Energy subscore on the Activation-Deactivation Adjective Check List [ Time Frame: Nine weeks ] [ Designated as safety issue: No ]
Energy subscore on the Activation-Deactivation Adjective Check List
Complete list of historical versions of study NCT00318019 on ClinicalTrials.gov Archive Site
Four global change questions [ Time Frame: Nine weeks ] [ Designated as safety issue: No ]
Four global change questions
Not Provided
Not Provided
 
Effect of OPC Factor on Energy Levels
The Effect of OPC Factor on Energy Levels in Healthy Individuals Aged 45-65: A Randomized Controlled Trial

In this study the food supplement OPC Factor will be tested to determine its effectiveness for increasing energy levels in healthy people aged 45-65 when compared to a placebo. All subjects will receive both active product and placebo at some time during the study. The study is nine weeks in duration. It involves three visits, taking an effervescent powder in water twice a day, and answering 24 multiple choice questions once a week. Subjects who complete the study can elect to receive a two month supply of the study product free of charge.

OPC Factor, a food supplement which contains grape seed extract, pine bark extract,vitamins and minerals, has shown during clinical observation the effect of raising energy levels in people aged 45-65. It is believed that the mechanism of action is based on enhanced production of ATP by mitochondria.

In this study subjects will be assigned by chance to either the active product group or the placebo group. Subjects will take the product for three weeks. Then there will be a two week wash out period followed by subjects being crossed over to the other group for a three week period. Subjects, assessors, and health providers will be masked as to who is in the active product group and who is in the placebo group. Subjects will meet with the primary investigator three times during the study, will fill out very short questions once a week, and receive phone calls once a week from study personnel.

This study is a randomized, placebo controlled, triple-blinded, cross-over study that tests the hypothesis that OPC Factor produces a response rate of 70% in the active product phase versus a 30% response rate during the placebo phase. A response is defined as at least a 20% absolute increase on the Energy subscale of the Activation-Deactivation Adjective Check List.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Healthy
  • Dietary Supplement: OPC Factor(TM)
    Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.
  • Other: Placebo
    Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
  • Experimental: OPC Factor(TM)
    Intervention: Dietary Supplement: OPC Factor(TM)
  • Placebo Comparator: Placebo
    Intervention: Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
27
April 2008
April 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. 45 to 65 years of age at the time of recruitment
  2. Healthy -- see exclusion criteria
  3. There is the possibility of at least a 20% absolute increase in the subject's energy subscale score of the Activation-Deactivation Adjective Checklist (AD ACL). For the purpose of meeting the inclusion criteria, the subject fills out the AD ACL with the following instructions: "Each of the words below describes feelings or moods. Please circle the rating next to each word that best describes your feelings during the past month. These instructions are different from the instructions used when the study endpoints are being measured so as to be consistent with the way the questionnaire was validated."

Exclusion Criteria:

  1. Any major medical or mental illness (including a history of bipolar disorder, borderline personality disorder, and schizophrenia)
  2. Medical diseases known to be associated with fatigue but not limited to:

    • AIDS
    • Anemia
    • Cancer or history of cancer (excluding basal cell carcinoma of the skin)
    • Chronic fatigue syndrome
    • Congestive heart failure
    • Chronic obstructive pulmonary disease (COPD)
    • Depression
    • Diabetes
    • Drug/alcohol dependence
    • Fibromyalgia
    • Hypertension that is uncontrolled or difficult to control
    • Hypothyroidism
  3. Subjects taking the following medical therapies:

    • Beta-blocking medications
    • Human growth hormone
    • Testosterone
    • Warfarin
  4. Subjects taking the following complementary and alternative medicine (CAM) products:

    • Feverfew
    • Garlic supplements
    • Ginseng
    • Red clover
  5. Women who have not gone through menopause - those women who have had one or more menstrual periods in the 12 months prior to the enrollment in the study
  6. The subject's score on the energy subscale of the AD ACL is at a level that precludes at least a 20% absolute increase of that score.
  7. Subjects who are unable to make their own decisions regarding informed consent
  8. Those subjects who have taken any of the medical therapies or CAM products listed but are no longer taking them are eligible to participate provided no other exclusion criteria are present and the subjects have not taken those therapies or products in the six months prior to enrollment.
Both
45 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00318019
804315
Not Provided
University of Pennsylvania
University of Pennsylvania
Not Provided
Principal Investigator: Patrick J LaRiccia, MD University of Pennsylvania
University of Pennsylvania
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP